AbbVie Inc v. Cipla Limited

Court

District Court, D. Delaware (D. Del.)
Official Court Website →

Assigned judge

Richard G. Andrews · 4,097 cases in index

Docket number

1:17-cv-01631

Cause

35:271 Patent Infringement
35 U.S.C. § 271 — Patent infringement

Nature of suit

835 Patent - Abbreviated New Drug Application(ANDA)
Hatch-Waxman patent disputes over a generic-drug (ANDA) application.

Jurisdiction

Federal Question

Jury demand

None

Date filed

11/10/2017

Date terminated

04/05/2018

1,113 Patent - ANDA cases in this court are indexed here.

Parties

• plaintiff · AbbVie Inc Pharmaceuticals & Biotechnology · 5032 cases
• defendant · Cipla Limited · 55 cases

About Patent - ANDA Lawsuits

ANDA patent cases arise when a generic-drug maker files an Abbreviated New Drug Application and the brand-name patent holder sues for infringement under the Hatch-Waxman Act.

Frequently Asked Questions

What is AbbVie Inc v. Cipla Limited?

AbbVie Inc v. Cipla Limited is a federal patent - anda lawsuit filed on 11/10/2017 in the District Court, D. Delaware. The case was terminated on 04/05/2018. ANDA patent cases arise when a generic-drug maker files an Abbreviated New Drug Application and the brand-name patent holder sues for infringement under the Hatch-Waxman Act.

What type of case is this?

It is classified as “Patent - ANDA” under the federal nature-of-suit system. ANDA patent cases arise when a generic-drug maker files an Abbreviated New Drug Application and the brand-name patent holder sues for infringement under the Hatch-Waxman Act.

What court is the case in?

The case is in the District Court, D. Delaware, docket number 1:17-cv-01631.

When was the case filed?

AbbVie Inc v. Cipla Limited was filed on 11/10/2017. It was terminated on 04/05/2018.

What law is the case brought under?

The docket lists the cause as 35 U.S.C. § 271 — Patent infringement.